Published in Semin Oncol on November 10, 2016
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Multiple myeloma. N Engl J Med (2011) 10.38
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol (2014) 4.37
Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood (2007) 4.08
A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 3.98
Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol (2007) 3.32
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood (2010) 3.21
Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst (2001) 2.62
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc (2004) 2.43
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Smoldering multiple myeloma. N Engl J Med (1980) 1.77
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med (1996) 1.51
A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol (2004) 1.38
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (2010) 1.21
Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia (2014) 1.20
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am Soc Hematol Educ Program (2013) 1.04
Smoldering multiple myeloma. Blood (2015) 1.03
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol (2015) 1.01
2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin (2016) 0.96
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia (2014) 0.88
Early mortality in multiple myeloma. Leukemia (2015) 0.79
The road to treating smoldering multiple myeloma. Clin Lymphoma Myeloma Leuk (2014) 0.77
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. Clin Adv Hematol Oncol (2014) 0.77
Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma (2016) 0.77
Multiethnic myeloma. Blood (2013) 0.77
Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiol Drug Saf (2016) 0.76